Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition for treating pain

A technology for drugs and opioids, applied in the field of pharmaceutical compositions for treating pain, can solve the problems of aggravating pain and tolerance, increasing drug dosage and the like

Active Publication Date: 2021-05-14
永展控股有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But based on conflicting evidence about opioid-induced pain from clinical and laboratory studies, the inventors had to reconsider their interpretation of the phenomenon
On the one hand, if the reduced efficacy of opioids is related to the mechanism of drug tolerance, then increasing the dose is clearly justifiable; on the other hand, if it is due to OIH, then blindly increasing the dose will only enhance the pro-nociceptive process in the body, thereby exacerbated pain and tolerance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating pain
  • Pharmaceutical composition for treating pain
  • Pharmaceutical composition for treating pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] Example 1. Screening of AC1 & 8 mixed inhibitors

[0104] A panel of biochemical screening assays was performed to find potential AC1 and AC8 co-inhibitors (or referred to as AC1 and 8 inhibitors). A cAMP assay, gene activation (pCREB) assay, and comprehensive physiological assays were performed in AC1 or AC8 expressing cell lines to screen for potential compounds A and B acting on AC1 and AC8. Both NB010 and NB011 were found to produce significant inhibition of AC1 as well as AC8 activity at 100 μM (see Table 1). For the test method, see Wang, H.S., et al., Identification of an Adenylyl Cyclase Inhibitor for Treating Neuropathic and Inflammatory Pain. Science Translational Medicine, 2011.3 (65).

[0105] Table 1. Effects of NB010 and NB011 on the activity of adenylyl cyclase subtypes 8 and 1

[0106]

Embodiment 2

[0107] Example 2. Evaluation of Anxiety-Related Cortical LTP by NB010 and NB011

[0108] Previous studies have shown that synaptic LTP induced by repetitive stimulation requires AC1 and AC8 activity (Zhuo, 2016). To assess the effects of NB010 and NB011 on the activity of neurons AC1 and AC8, the inventors recorded both forms of LTP in ACC cortical slices of adult mice.

[0109] As previously described, theta-stimulus stimulation induced a potentiation of synaptic responses lasting at least 40 min ( figure 1 A, n=8 slices). Pretreatment with NB010 (25 μM) can block the induction of ACC LTP ( figure 1 A, n=5 slices). Similar results were obtained using NB011 for preprocessing (see figure 2 , n=6 slices). In contrast, the same dose (25uM) of the non-selective AC inhibitor SQ22356 did not cause a significant decrease in pre-LTP ( figure 2 , n=5). As a comparison, pre-LTP was not blocked by GABApention (25 uM) (n=5). A recent report by ACC (Chen et al., 2014) also foun...

Embodiment 3

[0113] Example 3. Behavioral Effects of AC1 and AC1 & 8 Inhibitors on Morphine Tolerance

[0114] First, the inventors wanted to examine whether AC1 knockout mice affected morphine tolerance induced by repeated injections of morphine. As previously reported by the inventors, the inventors injected morphine (10 mg / kg, s.c.) daily for 7 days to measure morphine-induced tolerance. The inventors found that in AC1 knockout mice, compared with saline-treated wild-type mice (n=5-8 mice: day 7: control mice, MPE 18±6%, AC1KO, 40±8%) In contrast, morphine produced significantly greater analgesic effect; P image 3 ).

[0115] A previous study of AC1 and AC8 double knockout mice found significantly reduced morphine tolerance (Li et al., 2006). The inventors anticipate that AC1 & 8 inhibitors may also have the beneficial effect of reducing morphine tolerance. Similarly, pretreatment with NB010 or NB011 (5 mg / kg, i.p.) (n=5-8 mice, p<0.05 compared to control treatment in each case) pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new application of a pharmaceutical composition in the preparation of drugs for the treatment of tolerance and addiction caused by opioids, and specifically relates to the use of AC1 inhibitor NB001 and AC1&8 mixed inhibitors NB010 and NB011 in the preparation of drugs for the treatment of opioid-induced tolerance and addiction. Drug use in tolerance and addiction.

Description

technical field [0001] The invention relates to a new application of a pharmaceutical composition in the preparation of drugs for the treatment of tolerance and addiction caused by opioids, in particular to the use of AC1 inhibitor NB001 and AC1&8 mixed inhibitors NB010 and NB011 in the preparation of drugs for the treatment of tolerance caused by opioids. Drug use in acceptance and addiction. Background technique [0002] The term "opiate" has been used to designate pharmacologically active alkaloids derived from opium, such as morphine, codeine, and a number of semi-synthetic congeners of morphine. After the isolation of peptide compounds with morphine-like effects, the term opioid was introduced to generally refer to all drugs with morphine-like effects. Among opiates, various peptides exhibiting morphine-like activity are included, such as endorphins, enkephalins, and dynorphins. However, some sources use the generic term "opiate", in which case opiate is used intercha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/485A61K31/52A61K31/5377A61P25/04A61P25/22A61P25/24A61P17/04A61P25/02A61P29/00A61P37/06A61P25/16A61P13/00A61P15/10A61P25/30A61P25/32A61P9/00A61P11/00A61P1/00
CPCA61P15/10A61P25/30A61P9/00A61P25/02A61P25/22A61P25/32A61P37/06A61P25/04A61P25/24A61P1/00A61P11/00A61P25/16A61P29/00A61P13/00A61P17/04A61K31/485A61K31/52A61K31/5377A61K2300/00A61K45/06A61P25/00A61P29/02Y02A50/30
Inventor 卓敏
Owner 永展控股有限公司